Nanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment

Jan 2, 2025Molecular pharmaceutics

Using Tiny Particles Delivered Through the Nose to Treat Brain Cancer

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Innovative nanotechnology-based approaches may enhance drug delivery to glioblastoma tumors by exploiting the olfactory/trigeminal pathway.

Glioblastoma multiforme (GBM) presents significant treatment challenges due to the blood-brain barrier and blood-tumor barrier.
Nanosystems, including polymeric nanoparticles and lipid-based formulations, could improve targeted drug delivery to the brain with reduced systemic side effects.
Emerging therapies in gene therapy and immunotherapy may offer new avenues for GBM treatment.
Toxicological considerations related to intranasal delivery of nanosystems are crucial for ensuring safety in drug development.
Regulatory aspects are important for the successful advancement of intranasal products targeting GBM.

AI simplified

Glioblastoma multiforme (GBM) is considered to be one of the most devastating brain tumors with a shorter life expectancy. Several factors contribute to the dismal prognosis of GBM patients including the complicated nature of GBM, the ability of tumor cells to resist treatment, and the difficulty of delivering drugs to the brain because of barriers like the blood-brain barrier (BBB) and blood-tumor barrier (BTB). The unique challenges posed by the BBB in delivering therapeutic agents to the brain have led to the development of innovative nanotechnology-based approaches. By exploiting the olfactory/trigeminal pathway, nanosystems offer a promising strategy for targeted drug delivery to the brain, glioblastoma tumors in particular. This review contemplates varied nanocarriers, including polymeric nanoparticles, lipid-based nanosystems, in situ gel formulations, peptide, and stem cell-based nanoformulations, signifying their utility in brain targeting with minimal systemic side effects. Emerging trends in gene therapy and immunotherapy in the context of GBM treatment have also been discussed. Since safety is a paramount aspect for any drug product to get approved, this review also delves into toxicological considerations associated with intranasal delivery of nanosystems. Regulatory aspects and critical factors for the successful development of intranasal products are also explored in this review. Overall, this review underscores the significant advancements in nanotechnology for nose-to-brain delivery and its potential impact on GBM management.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

Nanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief